Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
Lisa A. Beck(University of Rochester Medicine), Arsalan Shabbir(Regeneron (United States)), Marjolein de Bruin‐Weller(Netherlands Center for Occupational Diseases), Ryszard Galus(Medical University of Warsaw), John T. O’Malley(Brigham and Women's Hospital), Mette Deleuran(Aarhus University Hospital), Robert Bissonnette(Innovaderm (Canada)), Takeshi Nakahara(Kyushu University), Ainara Rodríguez Marco(Sanofi (Spain)), Noah A. Levit(Fairfield University), Jing Xiao(Dalian Medical University), Jignesh Vakil(Sanofi (United States)), Faisal A. Khokhar(Regeneron (United States)), Seong Jun Seo(Soonchunhyang University)
Cited by 104
Related Papers
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report
|Journal of Allergy and Clinical Immunology|2010|2.3k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Atopic dermatitis
|Nature Reviews Disease Primers|2018|1.5k
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
|New England Journal of Medicine|2014|1.4k
Cytokine modulation of atopic dermatitis filaggrin skin expression
|Journal of Allergy and Clinical Immunology|2007|1.1k